Estrogen-dependent regulation of Eg5 in breast cancer cells

Anti-Cancer Drugs

Volumn 18, Issue 7, 2007, Pages 773-779

  Planas Silva, Maricarmen D ^a   Filatova, Irina S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Cell cycle; Eg5; Estrogen receptor; Kinesin

Indexed keywords

ANTIESTROGEN; DEFEROXAMINE; EG5 PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; KINESIN; MONASTROL; PACLITAXEL; PHORBOL 13 ACETATE 12 MYRISTATE; RIBONUCLEASE; TAMOXIFEN; TRITYL DERIVATIVE; TRITYLCYSTEINE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CELL CYCLE; CELL CYCLE S PHASE; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; KINESIN; MITOSIS; PYRIMIDINES; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; THIONES; UP-REGULATION;

EID: 34250889281     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280a02f2b     Document Type: Article

References (26)

1. cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995; 83:1159-1169.
2. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999; 286:971-974.
3. Sakowicz R, Finer JT, Beraud C, Crompton A, Lewis E, Fritsch A, et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004; 64:3276-3280.
4. Tao W, South VJ, Zhang Y, Davide JP, Farrell L, Kohl NE, et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005; 8:49-59.
5. Marcus AI, Peters U, Thomas SL, Garrett S, Zelnak A, Kapoor TM, et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and sensitive cancer cells. J Biol Chem 2005; 280:11569-11577.
6. Skoufias DA, DeBonis S, Saoudi Y, Lebeau L, Crevel I, Wade RH, et al. S-trityl-L-cysteine is a reversible, tight-binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. J Biol Chem 2006; 281:17559-17569.
7. Tarby CM, Kaltenbach RF III, Huynh T, Pudzianowski A, Shen H, Ortega-Nanos M, et al. Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series. Bioorg Med Chem Lett 2006; 16:2095-2100.
8. Davis DA, Sarkar SH, Hussain M, Li Y, Sarkar FH. Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer 2006; 6:22.
9. Liu M, Aneja R, Liu C, Sun L, Gao J, Wang H, et al. Inhibition of the mitotic kinesin Eg5 up-regulates HSP70 through the phophatidylinositol-3- kinase/Akt pathway in multiple myeloma cells. J Biol Chem 2006; 281:18090-18097.
10. Buzdar AU, Robertson JFR. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother 2006; 40:1572-1583.
11. Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 2004; 90 (Suppl):S2-S6.
12. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
13. Planas-Silva MD, Weinberg RA. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 1997; 17:4059-4069.
14. Planas-Silva MD, Bruggeman RD, Grenko RT, Smith JS. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun 2006; 341:73-81.
15. Kaiser A, Brembeck FH, Nicke B, Wiedenmann B, Riecken E-O, Rosewicz S. All-trans-retinoic acid-mediated growth inhibition involves inhibition of human kinesin-related protein HsEg5. J Biol Chem 1999; 274:18925-18931.
16. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 2005; 12:S47-S59.
17. Carroll JS, Prall OWJ, Musgrove EA, Sutherland RL. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem 2000; 275:38221-38229.
18. Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol 2000; 150:975-988.
19. WAFI/CIP1 induction. Cancer Lett 2001; 172:43-53.
20. Pahl PMB, Horwitz MA, Horwitz KB, Horwitz LD. Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells. Breast Cancer Res Treat 2001; 69:69-79.
21. Valette A, Gas N, Jozan S, Roubinet F, Dupont MA, Bayard F. Influence of 12-O-tetradecnoylphorbol-13-acetate on proliferation and maturation of human breast carcinoma cells (MCF-7): relationship to cell cycle events. Cancer Res 1987; 47:1615-1620.
22. 2/M cell cycle transition. FEBS Lett 1999; 444:32-37.
23. Doucas V, Spyrou G, Yaniv M. Unregulated expression of c-Jun or c-Fos proteins but not Jun D inhibits oestrogen receptor activity in human breast cancer derived cells. EMBO J 1991; 10:2237-2245.
24. Lee CSL, Koga M, Sutherland RL. Modulation of estrogen receptor and epidermal growth factor receptor mRNAs by phorbol ester in MCF 7 breast cancer cells. Bioch Biophys Res Commun 1989; 162:415-421.
25. Martin MB, Garcia-Morales P, Stoica A, Solomon HB, Pierce M, Katz D, et al. Effects of 12-O-tetradecanoylphorbol-13-acetate on estrogen receptor activity in MCF-7 cells. J Biol Chem 1995; 270:25244- 25251.
26. Koller E, Propp S, Zhang H, Zhao C, Xiao X, Chang M, et al. Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development. Cancer Res 2006; 66:2059-2066.